Tuesday Bell Watch: Breakout Idea (XRTX) Is A Tiny Float Nasdaq Profile In Need Of Attention

Did you see my latest breakout idea? If not, it popped-off this past Thursday. Tuesday Bell Watch: Breakout Idea (XRTX) Is A Tiny Float Nasdaq Profile In Need Of Attention March 19th Dear Reader, Did you see my latest breakout idea? If not, it popped-off this past Thursday. Running from an open of $1.99 to a new 5-month high of $2.36, the Nasdaq profile unleashed a surge of approximately 18% intraday. But that's not the only update I've got for you. My alert from March 6th has now clipped a max move of approximately 10.5% after huge news last week. A little bit slower of a mover, but a double-digit champ within 2 weeks nonetheless! Listen. I'm not going to beat around the bush. I've identified a new breakout idea. And this one? It could be a doozy! With a tiny float under 2Mn shares, volatility could be injected into this Nasdaq profile in the blink of an eye. Furthermore, this profile boasts an extensive analyst price target. Alliance Global Partners has suggested a $14 price target reported over at [TipRanks](. From Monday's opening valuation, that target suggests upside potential well over 150+%! It gets better. As of Monday afternoon, this Nasdaq profile had triggered at least 8 different technical indicators over at Barchart including the website's composite "Trend Seeker" indicator. That's a lot to take in. But, now is not the time to pump the breaks. Instead, it's time to pull up Nasdaq breakout idea: *XORTX Therapeutics Inc. (XRTX)* XORTX Therapeutics is a late stage clinical pharmaceutical company dedicated to developing innovative therapies to improve the quality of life of patients with progressive kidney disease. And based on these potential breakout catalysts, XRTX needs immediate attention. Check them out: #1. Volatility Watch - A Low Float Could Create An Explosive Situation. #2. Bullish Technicals - Key Triggered Indicators May Suggest Breakout Potential. #3. New Patent Submission - XORTX Aims To Protect New Discoveries And Strategies. #4. XRTX Could Be Growing Strong Support At 3 Key Technical Lines. But more on those in a second... XORTX Therapeutics - Immediate Points Of Consideration - The company is developing drug-based therapies for serious progressive kidney diseases with a high unmet medical need, including Autosomal Dominant Polycystic Kidney Disease (ADPKD), Diabetes Type-2 Nephropathy (T2DN) and Acute Kidney Injury (AKI). - Three patent families derived from their proprietary pipeline-in-a-product technology with broad therapeutic claims. Multiple third-party studies with well-understood Oxypurinol have characterized the mechanism of action (MoA) in over 700 patients treated, including multiple Ph2 studies. Patent protection until 2034. - Clear focus on XRx-008 program for ADPKD with a $1.0-1.8Bn per year revenue potential for XRTX in the US alone: strong unmet medical need; only one drug approved subject to a black box warning with market exclusivity expiring in 2025; Orphan Drug Designated granted by FDA; path to accelerated approval confirmed; potential for early revenue in 2026/7 to replace Tolvaptan by Otsuka. - Short-term catalyst: signing of a global licensing deal in 2024/2025 may provide nondilutive funding to support the Ph3 pivotal registration clinical trial with approximately 200 patients. - Strong cash position of $5.2Mn - runway for 14 months. - Senior team led by CEO Allen W. Davidoff, Ph.D was responsible for Oxypurinol development in prior ventures and knows how to build shareholder value (Cynapsus Therapeutics was acquired for $624Mn and Trillium Therapeutics was bought for $2.2Bn by Pfizer). First-in-class Product Candidate Ready for Ph3 Clinical Trials of Xanthine Oxidase Inhibitor for ADPKD XORTX's pipeline targets areas of high unmet medical need, including Autosomal Dominant Polycystic Kidney Disease (ADPKD), Acute Kidney Injury (AKI) due to CV19, and Type 2 Diabetic Nephropathy (T2DN). End-stage Renal Disease (ESRD) [market valued at]( around $114Bn globally in 2022 and is expected to reach $183.9Bn by 2032. ADPKD Estimated Addressable Market In The U.S. ADPKD – Only One Therapy Is Approved While Suboptimal Treatment Options Remain - 160,000 patients diagnosed with ADPKD in the U.S. (1) - ADPKD is the largest kidney disease market with a genetic origin. - A majority of ADPKD patients require dialysis or kidney transplantation. - Otsuka's JYNARQUE® (tolvaptan) was approved in 2018 for the treatment of ADPKD with black box warning – “for risk of serious liver injury." - Annual Treatment Cost of JYNARQUE® (tolvaptan) ~$156k. Otsuka reported 2022 sales of tolvaptan of $962Mn. More than ~7,000 ADPKD patients have been treated with tolvaptan. (2) - 95% of ADPKD patients can’t take or tolerate JYNARQUE® (tolvaptan). (3) About The XRx-008 Program Oxypurinol is a purine based XOI with important pharmacologic characteristics ideal for administration to individuals with ADPKD. Key pharmacologic attributes include: 1. The ability to act in the circulation, kidney and cardiovascular tissue and inhibit the production of uric acid and so attenuate the mechanism of injury and accelerating effect of XO on progressing diseases. 2. XORTX’s proprietary formulation of oxypurinol, XORLO™, provides substantially increased absorption of oxypurinol. Metabolism of oxypurinol is minimal and it is eliminated by the kidneys unchanged. This approach provides an effective, well tolerated drug with an extensive clinical safety experience suggesting the Company’s XRx-008 program has the capacity to provide superior XOI to slow the accelerating decline of kidney function in patients ADPKD with coexistent hyperuricemia. Sources: [Company Presentation.]( ----- (Nasdaq: XRTX): 4 Potential Breakout Catalysts To Know Now As mentioned above, XRTX has several potential breakout catalysts to start tracking. Check them out: #1. Volatility Watch - A Low Float Could Create An Explosive Situation. According to the [Yahoo Finance]( website, XRTX has a tiny low float. The website reports this profile to have approximately 1.82Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could positive company news in early 2024 provide a near term spark for XRTX? ----- #2. Bullish Technicals - Key Triggered Indicators May Suggest Breakout Potential. At 2:30PM EST Monday, [Barchart]( was reporting XRTX to have a multitude of bullish technical indicators across the short, medium, and long term. Here's a quick list: Short Term Indicators - 20 Day Moving Average - 20 - 50 Day MACD Oscillator - 20 - 100 Day MACD Oscillator Medium Term Indicators - 50 Day Moving Average - 50 - 100 Day MACD Oscillator Long Term Indicators - 100 Day Moving Average - 150 Day Moving Average - 200 Day Moving Average Not only those, but Barchart's composite "Trend Seeker" indicator was triggered, too. Make sure to keep a close eye on this list. ----- #3. New Patent Submission - XORTX Aims To Protect New Discoveries And Strategies. XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease (“CKD”). This patent is designed to protect new discoveries and strategies for the treatment of individuals with varied degrees of kidney function in the setting of CKD. Importantly, this patent entitled “Oral and Sublingual Formulations of Xanthine Oxidase Inhibitors and Methods of Treating Disease” outlines new formulations and methods for safer and more effective the use of xanthine oxidase inhibitors (XOI) in the setting of CKD in particular autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy (DN), IgA nephropathy, lupus nephritis and focal segmental glomerulosclerosis. ... Dr. Allen Davidoff, CEO of XORTX, commented, “The Bridging Pharmacokinetic Study reported this year provided a wealth of clinical data regarding the potential substantive benefit of the novel formulations of the xanthine inhibitor class of drugs. Analysis of this data set, the use of in silico based pharmacokinetic modeling of data from the XRX-OXY-101 clinical trial, and further innovation, resulted in a deeper understanding of how to address the challenges of dosing in progressing kidney disease. This patent application is intended to claim new opp's to enhance how the xanthine oxidase inhibitor class of drugs may be dosed in the future. Importantly, how to further improve the safe and effective administration of this class of drugs, including oxypurinol.” [Read the full article here.]( ----- #4. XRTX Could Be Growing Strong Support At 3 Key Technical Lines. Take a look at XRTX's 3-month chart below: As of roughly 2:30PM EST Monday, XRTX was trading above 3 key technical lines. With it already blasting above its 50-Day SMA and its 13-Day Exponential Moving Average (EMA) in February, XRTX's move above its 200-Day SMA early in March could prove to be a difference maker. If potential support strengthens at those technical levels, it could help XRTX to keep pushing the limits of the top-right section of its chart. And don't forget, with the [$14 price target]( mentioned above on XRTX, there could still be over 150% potential upside from its opening valuation Monday. Do yourself a favor and watch XRTX's chart and technical lines closely this week. ----- XRTX Recap - 4 Potential Breakout Catalysts To Know Now #1. Volatility Watch - A Low Float Could Create An Explosive Situation. #2. Bullish Technicals - Key Triggered Indicators May Suggest Breakout Potential. #3. New Patent Submission - XORTX Aims To Protect New Discoveries And Strategies. #4. XRTX Could Be Growing Strong Support At 3 Key Technical Lines. ----- Coverage is officially initiated on (Nasdaq: XRTX). When updates are available this week, I'll get them out quickly. Talk soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer Sources: (1) Vicente E. Torres March 2021 AJKD, (2) A.G.P./Alliance Global Partners Research, (3) Wim Van Biesen, Jan 2019, NDT (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor (FI) is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc.laim.er here: [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 3/18/24 and ending on 3/19/24 to publicly disseminate information about (XRTX) via Website, Email and SMS. SWN Media LLC was paid twenty thousand USD via bank wire transfer. We own zero shares of (XRTX). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and XORTX Therapeutics Inc., TD Media LLC has been hired for a period beginning on 03/11/2024 and ending on 04/05/2024 to publicly disseminate information about (XRTX:US) via digital communications. We have been paid one hundred thousand dollars USD. We own zero shares of (XRTX:US). Pursuant to an agreement between TD Media LLC and XORTX Therapeutics Inc., TD Media LLC has been hired for a period beginning on 04/08/2024 and ending on 05/03/2024 to publicly disseminate information about (XRTX:US) via digital communications. We have been paid an additional one hundred fifty thousand dollars USD. To date we have been paid two hundred fifty thousand dollars USD to disseminate information about (XRTX:US) via digital communications. We own zero shares of (XRTX:US). [( A member of SWN Media LLC is also a member of Media 1717 LLC which owns and operates KryptonStreet.com. Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/18/2024 and ending on 03/19/2024 to publicly disseminate information about (XRTX:US) via digital communications. Media 1717 has been paid seven thousand five hundred dollars USD and owns zero shares of (XRTX:US). A member of SWN Media LLC is also a member of Headline Media LLC which owns and operates MarketCrux.com. Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 03/18/2024 and ending on 03/19/2024 to publicly disseminate information about (XRTX:US) via digital communications. Headline Media has been paid seven thousand five hundred dollars USD and owns zero shares of (XRTX:US). Fierce | 4834 NW 2nd Ave, Unit #388, Boca Raton, FL 33431 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.ccsend.com